Clinical trials: Anticoagulant Drugs
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atrial Fibrillation
Patient Convenience Study
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02597920
- Where
- 148 sites in Belgium, Denmark and 5 more
- Volunteers
- 1,852 people
- Sponsor
- Boehringer Ingelheim
Patients Undergoing Microvascular Surgery
Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction
A comparative study to reveal if the use of Bemiparine (Hibor) versus Enoxaparin (Clexane) as an antithrombotic agent, shows an advantage on the rate of thrombotic and haemorrhagic events in microsurgicals free flaps during head…
- Trial name
- NCT02808273
- Testing
- Bemiparine
- Where
- Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Cardiovascular Diseases
Effectiveness of "Medisinstart"
"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition.
- Trial name
- NCT02261402
- Testing
- Medisinstart
- Where
- 67 sites in Norway
- Volunteers
- 1,480 people
- Sponsor
- Apokus AS
Atrial Fibrillation, Coronary Artery Disease
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months…
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Stable Angina, Stable Chronic Angina
- Trial name
- EPIC-CAD (NCT03718559)
- Testing
- Edoxaban Monotherapy, Edoxaban plus Single Antiplatelet Agent
- Where
- 18 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Gi-Byoung Nam
Venous Thrombosis or Pulmonary Embolism
What Treatment for Patients With Phlebitis or Pulmonary Embolism ?
The objective of the "anticoagchoice" study is to analyze the preferences of people suffering from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt the medical prescriptions.
- Trial name
- AntiCoagChoice (NCT03889457)
- Testing
- anticoagulation choice
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Rennes University Hospital
Direct Oral Anticoagulant, Hemmorhage
Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly
This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.
- Conditions
- Direct Oral Anticoagulant, Hemmorhage, Elderly, Muscle Mass
- Trial name
- SARCORRHAGED (NCT07173075)
- Testing
- impedancemetry
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Clermont-Ferrand
Pulmonary Arterial Hypertension
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension (CTE-PHT) prevention, the frequent prescription (50…
- Trial name
- HEMA-HTP (NCT02800941)
- Testing
- Oral anticoagulant treatment
- Where
- 4 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Anticoagulant
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Pharmacodynamic Study - Phase I Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/mL; Blau Farmacêutica S/A.
- Trial name
- NCT05788900
- Testing
- Heparin
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Blau Farmaceutica S.A.
Anticoagulants; Increased
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
Randomized pilot trial of restarting DOACs at 1 week versus 4 weeks after traumatic intracranial hemorrhage
- Trial name
- NCT04891861
- Testing
- Apixaban
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Cerebrovascular Stroke, Intracranial Hemorrhages
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore…
- Conditions
- Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases
- Trial name
- NCT03772457
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation, Atrial Flutter
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-AF (NCT03129490)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 38 sites in Denmark
- Volunteers
- 11,000 people
- Sponsor
- Herlev and Gentofte Hospital
Cancer-associated Thrombosis
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis.
- Trial name
- NCT07388056
- Testing
- Anticoagulant
- Volunteers
- 169 people
- Sponsor
- Thammasat University
Oral Anticoagulants, Invasive Procedure
Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology
Patients receiving long-term oral anticoagulant (defined as duration of treatment of at least 1 month of Direct Oral Anticoagulant (DAOC) or Vitamin K Antagonist (VKA)) and referred for an invasive procedure (oral surgery…
- Trial name
- PRADICO (NCT03150303)
- Where
- France
- Volunteers
- 532 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD
Healthy
Safety and Dosing Evaluation of REG1 Anticoagulation System
This 1-week study will test the safety and dosing of an anticoagulation system called REG1 that is designed to improve control of "blood thinning." Patients with heart attack and other conditions require treatment with an…
- Trial name
- NCT00113997
- Testing
- REG1
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture
Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage.
- Conditions
- ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF), Mitral Valve Surgery, Stroke (in Patients With Atrial Fibrillation)
- Trial name
- ATRI-LASH (NCT07360899)
- Testing
- LAA closure using the AtriLASH
- Where
- Serbia
- Volunteers
- 200 people
- Sponsor
- Institute of Cardiovascular Diseases, Vojvodina
Coronary Artery Disease, Atrial Fibrillation
Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation
The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation is associated with improved clinical outcomes in patients on ASA and an oral anticoagulant.
- Trial name
- ISAR-TRIPLE (NCT00776633)
- Testing
- aspirin, clopidogrel, oral anticoagulation
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 614 people
- Sponsor
- Deutsches Herzzentrum Muenchen